Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Enterprise Value (2023 - 2025)

CG Oncology (CGON) has disclosed Enterprise Value for 3 consecutive years, with -$742.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value changed 0.02% year-over-year to -$742.2 million, compared with a TTM value of -$742.2 million through Dec 2025, changed 0.02%, and an annual FY2025 reading of -$742.2 million, changed 0.02% over the prior year.
  • Enterprise Value was -$742.2 million for Q4 2025 at CG Oncology, down from -$680.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$187.7 million in Q4 2023 and bottomed at -$742.2 million in Q4 2025.
  • Average Enterprise Value over 3 years is -$595.7 million, with a median of -$661.1 million recorded in 2025.
  • The sharpest move saw Enterprise Value plummeted 295.37% in 2024, then dropped 0.02% in 2025.
  • Year by year, Enterprise Value stood at -$187.7 million in 2023, then tumbled by 295.37% to -$742.0 million in 2024, then dropped by 0.02% to -$742.2 million in 2025.
  • Business Quant data shows Enterprise Value for CGON at -$742.2 million in Q4 2025, -$680.3 million in Q3 2025, and -$661.1 million in Q2 2025.